Nutra Pharma Corp., a biotechnology holding company that owns non-exclusive license rights to patents and intellectual property related to the development of drugs for HIV and Multiple Sclerosis ("MS"), today announced that it has retained Rubenstein Investor Relations, Inc. as its investor relations consultants. Commenting on the announcement, Rik Deitsch, CEO of Nutra Pharma, stated, "We are pleased to announce our alliance with Rubenstein Investor Relations, a full-service public relations and investor relations firm with a proven track record. We are confident that Rubenstein Investor Relations will be successful in communicating our exciting story to Wall Street and the financial media."
Richard Rubenstein, President of Rubenstein Investor Relations, noted, "We are proud to have been chosen by Nutra Pharma to assist in its investor relations campaign. We look forward to implementing a comprehensive investor relations program tailored to meet the Company's objectives."
This press release contains forward-looking statements. The words or phrases "would be," "will allow," "intends to," "will likely result," "are expected to," "will continue," "is anticipated," "estimate," "project," or similar expressions are intended to identify "forward-looking statements." Actual results could differ materially from those projected in Nutra Pharma's ("the Company") business plan. The Company's business is subject to various risks, which are discussed in the Company's filings with the Securities and Exchange Commission ("SEC"). Retaining Rubenstein Investor Relations should not be construed as an indication in any way whatsoever of the value of the Company or its common stock. The Company's filings may be accessed at the SEC's Edgar system at www.sec.gov. Statements made herein are as of the date of this press release and should not be relied upon as of any subsequent date. The Company cautions readers not to place reliance on such statements. Unless otherwise required by applicable law, we do not undertake, and we specifically disclaim any obligation, to update any forward-looking statements to reflect occurrences, developments, unanticipated events or circumstances after the date of such statement.